CG Oncology Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 4.26, 97.34, 486.07, 960.76, 1507.07 ], "ebit_estimate": [ -276.45, -281.29, -33.57, 324.69, 771.04 ], "ebitda_estimate": [ -274.69, -279.71, -41.22, null, null ], "net_income_estimate": [ -246.44, -250.45, -3.28, 331.41, 674.41 ], "per_share_eps_estimate": [ -2.89, -2.88, -0.29, 2.92, 6.27 ], "eps_nri_estimate": [ -2.87, -2.82, -0.32, 2.92, 6.27 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 12.19, 10.87, 12.33, null, null ], "pretax_income_estimate": [ -247.96, -264.8, 5.58, 443.47, 899.91 ], "operating_cash_flow_per_share_estimate": [ -2.2, -1.79, 2.61, 0.21, null ], "roa_estimate": [ -28.9, -20.8, null, null, null ], "roe_estimate": [ -28.76, -21.04, 8.98, null, null ], "gross_margin_estimate": [ 85, 85.5, 86.2, 88.1, 89.4 ], "operating_cash_flow_estimate": [ -185.66, -151.29, 220.6, 17.75, null ], "pettm_estimate": [ 0, 0, 0, 25.77, 12.01 ], "long_term_growth_rate_mean": 43.34, "long_term_revenue_growth_rate_mean": "475.49", "future_per_share_eps_estimate_growth": 44.47, "future_eps_nri_estimate_growth": 43.34, "future_revenue_estimate_growth": 475.49, "future_ebit_estimate_growth": 40.52, "future_ebitda_estimate_growth": 36.59, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 68.85, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": 7.48, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 0.33, 1.29, 0.93, null, 12.8, 19.7, 35.8 ], "ebit_estimate": [ -66.16, -68.48, -74.14, -78.6, -65.55, -64.5, -50.45 ], "ebitda_estimate": [ -65.72, -64.76, -70.97, null, null, null, null ], "net_income_estimate": [ -57.04, -60.73, -66.46, -74.5, -61.65, -60.7, -46.75 ], "per_share_eps_estimate": [ -0.67, -0.71, -0.76, -0.84, -0.72, -0.71, -0.6 ], "eps_nri_estimate": [ -0.66, -0.71, -0.75, -0.89, -0.81, -0.75, -0.6 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -57.98, -61.92, -68.64, -74.5, -61.65, -60.7, -46.75 ], "operating_cash_flow_per_share_estimate": [ -0.51, -0.58, -0.73, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ -27.51, -30.38, -35.28, null, null, null, null ], "gross_margin_estimate": [ 85, 85, 85, null, 85, 85, 85 ], "operating_cash_flow_estimate": [ -43.11, -49.02, -61.7, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 43.34, "long_term_revenue_growth_rate_mean": "475.49", "future_per_share_eps_estimate_growth": 44.47, "future_eps_nri_estimate_growth": 43.34, "future_revenue_estimate_growth": 475.49, "future_ebit_estimate_growth": 40.52, "future_ebitda_estimate_growth": 36.59, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 68.85, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": 7.48, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }